Background pattern of a brain with neural connections

Team Mann

Deciphering the Aggregatome: Unraveling Alpha-Synuclein Seeding Drivers in Parkinson’s Disease across Human Biomaterials

2026-Present

Parkinson’s disease progression varies significantly among patients, with alpha-synuclein (aSyn) aggregation as a key pathological hallmark. However, factors influencing aSyn seeding remain poorly understood. We will characterize biochemical and biophysical determinants of aSyn seeding across brain, CSF, blood, skin and stool. Our multidisciplinary team brings together expertise in seed amplification assay development, mass spectrometry-based proteomics, advanced biochemical methods, neuropathological characterization and access to exclusive patient cohorts with longitudinally matched biosamples. We will: 1) define differentially seeding-competent aSyn species and their molecular signatures; 2) validate their functional relevance in cellular models; 3) establish their association with disease progression and clinical phenotypes.

Tags
AggregationAlpha-synucleinArtificial intelligenceBiomarker discoveryBloodBrainCellular assaysDisease heterogeneityPD subtypesProteomicsSeeding assays

Contributions

Stay tuned—this is where the team’s scientific contributions will be shared.

Accolades

Check back soon to see how this team is being recognized.

In the News

Aligning Science Across Parkinson’s and The Michael J. Fox Foundation Expand Global Research Initiative with $261M Investment Toward Personalized Treatments

Aligning Science Across Parkinson’s and The Michael J. Fox Foundation Expand Global Research Initiative with $261M Investment Toward Personalized Treatments

04/28/2026 — Today, Aligning Science Across Parkinson’s (ASAP), in partnership with The Michael J. Fox Foundation for Parkinson’s Research (MJFF), announced $261 million in new grant funding for the Collaborative Research Network (CRN) to map the biological blueprint of Parkinson’s disease and build a standardized toolkit of global research resources that are needed to turn discoveries into treatments.

Our Research Teams

Members of the CRN work diligently to advance our understanding of Parkinson’s disease. Learn more about recent CRN discoveries and achievements.